Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: Activity and toxicity profile

International Journal of Oncology

Volumn 37, Issue 6, 2010, Pages 1389-1397

  Dreischalück, Johannes ^a   Schwöppe, Christian ^a   Spieker, Tilmann ^b   Kessler, Torsten ^a   Tiemann, Klaus ^a   Liersch, Ruediger ^a   Schliemann, Christoph ^a   Kreuter, Michael ^c   Kolkmeyer, Astrid ^a   Hintelmann, Heike ^a   Mesters, Rolf M ^a   Berdel, Wolfgang E ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cancer; Subcutaneous therapy; Truncated tissue factor; Tumor homing peptides; Vascular targeting

Indexed keywords

HYBRID PROTEIN; TRUNCATED TISSUE FACTOR NGR PEPTIDE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; DEAMINATION; DRUG PROTEIN BINDING; ENDOTHELIUM CELL; FIBROSARCOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOEMBOLISM; TUMOR BLOOD FLOW; UPREGULATION; VASCULAR TUMOR;

ANGIOGENESIS INHIBITORS; ANIMALS; BLOOD VESSELS; CELL LINE, TUMOR; CELLS, CULTURED; DRUG DELIVERY SYSTEMS; HUMANS; INFARCTION; INJECTIONS, SUBCUTANEOUS; MICE; MICE, NUDE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; RECOMBINANT FUSION PROTEINS; THROMBOPLASTIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78649965848     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000790     Document Type: Article

References (40)

1. Folkman J: Angiogenesis in cancer, vascular, reumatoid and other disease. Nat Med 1: 27-31, 1995.
2. Padró T, Ruiz S, Bieker R, et al: Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 95: 2637-2644, 2000.
3. Chaplin DJ, Dougherty GJ and Siemann DW: Vascular disrupting agents. In: Antiangiogenic Cancer Therapy. Davis DW, Herbst R and Abbruzzese JL (eds). CRC Press, Boca Raton, pp329-364, 2008.
4. Ferrara N and Alitalo K: Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5: 1359-1364, 1999.
5. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, flourouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
6. Denekamp J: Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 45: 136-139, 1982.
7. Kessler T, Fehrmann F, Bieker R, Berdel WE and Mesters RM: Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies. Curr Drug Targets 8: 257-268, 2007.
8. Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Jaffe EA and Old LJ: Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci USA 89: 10832-10836, 1992.
9. Kessler TA, Pfeifer A, Silletti S, et al: Matrix metalloproteinase/ integrin interactions as target for anti-angiogenic treatment strategies. Ann Hematol 81 (Suppl 2): S69-S70, 2002.
10. Brooks PC, Clark RA and Cheresh DA: Requirement of vascular Integrin alpha V beta 3 for angiogenesis. Science 264: 569-571, 1994.
11. Koivunen E, Wang B and Ruoslahti E: Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (N Y) 13: 265-270, 1995.
12. Senger DR, Claffey KP, Benes JE, Perruzzi CA, Sergiou AP and Detmar M: Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins. Proc Natl Acad Sci USA 94: 13612-13617, 1997.
13. Burg MA, Pasqualini R, Arap W, Ruoslahti E and Stallcup WB: NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res 59: 2869-2874, 1999.
14. Arap W, Pasqualini R and Ruoslahti E: Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279: 377-380, 1998.
15. Ellerby MH, Arap W, Ellerby LM, et al: Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5: 1032-1038, 1999.
16. Hood JD, Bednarski M, Frausto R, et al: Tumor regression by targeted gene delivery to the neovasculature. Science 296: 2404-2407, 2002.
17. Ran S, He J, Xianming H, Soares M, Scothorn D and Thorpe PE: Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice. Clin Cancer Res 11: 1551-1562, 2005.
18. Ruoslahti E: Targeting tumor vasculature with homing peptides from phage display. Semin Cancer Biol 10: 435-442, 2000.
19. Tozer GM, Kanthou C and Baguley BC: Disrupting tumour blood vessels. Nat Rev Cancer 5: 423-435, 2005.
20. Morrissey JH, Macik BG, Neuenschwander PF and Comp PC: Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 81: 734-744, 1993.
21. Huang X, Molema G, King S, Watkins L, Edgington TS and Thorpe PE: Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275: 547-550, 1997.
22. Nilsson F, Kosmehl H, Zardi L and Neri D: Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 61: 711-716, 2001.
23. Liu C, Huang H, Donate F, et al: Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer Res 62: 5470-5475, 2002.
24. Ran S, Gao B, Duffy S, Watkins L, Rote N and Thorpe PE: Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res 58: 4646-4653, 1998.
25. Kessler T, Bieker R, Padró T, et al: Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature. Clin Cancer Res 11: 6317-6324, 2005.
26. Pasqualini R, Koivunen E, Kain R, et al: Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 60: 722-727, 2000.
27. Curnis F, Arrigoni G, Sacchi A, et al: Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 62: 867-874, 2002.
28. Corti A, Curnis F, Arap W and Pasqualini R: The neovasculature homing motif NGR: more than meets the eye. Blood 112: 2628-2635, 2008.
29. Curnis F, Longhi R, Crippa L, et al: Sponaneous formation of L-isoaspartate and gain of function in fibronectin. J Biol Chem 281: 36466-36476, 2006.
30. Bieker R, Kessler T, Schwöppe C, et al: Infarction of tumor vessels by NGR-peptide directed targeting of tissue factor. Experimental results and first-in-man experience. Blood 113: 5019-5027, 2009.
31. Kessler T, Schwöppe C, Liersch R, et al: Generation of fusion proteins for selective occlusion of tumor vessels. Curr Drug Discov Technol 5: 1-8, 2008. (Pubitemid 351364567)
32. Ruf W, Rehemtulla A, Morrissey JH and Edgington TS: Phospholipid- independent and -dependent interactions required for tissue factor receptor and cofactor function. J Biol Chem 266: 2158-2166, 1991. (Pubitemid 21909043)
33. Lohmaier S, Ghanem A, Veltmann C, Sommer T, Bruce M and Tiemann K: In vitro and in vivo studies on continuous echocontrast application strategies using SonoVue in a newly developed rotating pump setup. Ultrasound Med Biol 30: 1145-1151, 2004.
34. Tiemann K, Veltmann C, Ghanem A, et al: The impact of emission power on the destruction of echo contrast agents and on the origin of tissue harmonic signals using power pulse-inversion imaging. Ultrasound Med Biol 27: 1525-1533, 2001. (Pubitemid 34028109)
35. Banner DW, D'Arcy A, Chène C, et al: The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 380: 41-46, 1996.
36. Aina OH, Sroka TC, Chen ML and Lam KS: Therapeutic cancer targeting peptides. Biopolymers 66: 184-199, 2002.
37. Pasqualini R and Arap W: Profiling the molecular diversity of blood vessels. Cold Spring Harb Symp Quant Biol 67: 223-225, 2002.
38. Bhagwat S, Lahdenranta J, Giordano R, Arap W, Pasqualini R and Shapiro L: CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood 97: 652-659, 2001.
39. Bhagwat S, Petrovic N, Okamoto Y and Shapiro L: The angiogenic regulator CD13/APN is a transcriptional target of Ras signaling pathways in endothelial morphogenesis. Blood 101: 1818-1826, 2003.
40. Philipp J, Dienst A, Unruh M, et al: Soluble tissue factor induces coagulation on tumor endothelial cells in vivo if coadministered with low-dose lipopolysaccharides. Arterioscler Thromb Vasc Biol 23: 905-910, 2003.